Where I see patients (4)
My reviews
Selected research
-
A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
Prostate cancer and prostatic diseases
-
Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
-
Development of CD46 targeted alpha theranostics in prostate cancer using 134Ce/225Ac-Macropa-PEG4-YS5.
Theranostics
Clinical trials
Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
rPFS is defined as the amount of time from the initiation of study therapy and the day of first documented radiographic disease progression per RECIST version 1.1 and PCWG3 criteria. The proportion of patients without radiographic...
Recruiting
FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostat...
A minimum of 3 patients will be treated at each dose level. If < 33%of patients (i.e. 0 of 3 patients, or 1 of 6 patients) within a cohort have a dose-limiting toxicity (DLT in Cycle 1, then enrollment of the next cohort may comme...
Recruiting
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant ...
Defined as either objective response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (complete response (CR), partial response (PR)) or confirmed >= 50% decline from serum prostate-specific antigen (PSA) at ...
Recruiting
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With So...
On overall response will be reported as a percentage of participants with a complete response (CR) or partial response (PR) as measured by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Recruiting
A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastati...
To compare the PFS between treatment arms. PFS is defined as the time (month) interval between date of randomization and date of radiographic disease progression or death for those without prior evidence of progression, as assesse...
Recruiting
4.9